Recent Publications

FRONTIERS IN IMMUNOLOGY

Human CD4 + CD25 + CD226 – Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4 + CD25 + CD127 lo/- Tregs for Adoptive Cell Therapy

Front Immunol. 2022 May 26;13:873560. doi: 10.3389/fimmu.2022.873560. PMID: 35693814; PMCID: PMC9178079.

Authors:
Brown ME, Peters LD, Hanbali SR, Arnoletti JM, Sachs LK, Nguyen KQ, Carpenter EB, Seay HR, Fuhrman CA, Posgai AL, Shapiro MR, Brusko TM. 

Frontiers in Immunology

The Immunoregulatory Role of the Signal Regulatory Protein Family and CD47 Signaling Pathway in Type 1 Diabetes REVIEW

Front Immunol. 2021 Sep 16;12:739048. doi: 10.3389/fimmu.2021.739048. PMID: 34603322; PMCID: PMC8481641.

Authors: 
Sharp RC, Brown ME, Shapiro MR, Posgai AL, Brusko TM. 

Protein Tyrosine Phosphatase Nonreceptor type 22 (PTPN22)

Perry DJ, Peters LD, Lakshmi PS, Zhang L, Han Z, Wasserfall CH, Mathews CE, Atkinson MA, Brusko TM. Overexpression of the PTPN22 Autoimmune Risk Variant LYP-620W Fails to Restrain Human CD4+ T Cell Activation. J Immunol. 2021 Aug 1;207(3):849-859. doi: 10.4049/jimmunol.2000708. Epub 2021 Jul 23.

CD226 (DNAM-1) rs763361

Shapiro MR, Yeh WI, Longfield JR, Gallagher J, Infante CM, Wellford S, Posgai AL, Atkinson MA, Campbell-Thompson M, Lieberman SM, Serreze DV, Geurts AM, Chen YG, Brusko TM. CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation. Front Immunol. 2020 Sep 4;11:2180. doi: 10.3389/fimmu.2020.02180.

Perry DJ, Titov AA, Sobel ES, Brusko TM, Morel L. Immunophenotyping reveals distinct subgroups of lupus patients based on their activated T cell subsets. Clin Immunol. 2020 Dec;221:108602. doi: 10.1016/j.clim.2020.108602. Epub 2020 Sep 29.

Immunophenotyping_Dan

Editorial: Footprints of Immune Cells in the Type 1 Diabetic Pancreas

Editorial Image